Momenta Pharma (MNTA) Downgraded To 'Neutral' By UBS Securities

Posted on July 20, 2012 at 13:57 PM EDT

UBS Securities analyst Ami Fadia downgraded rating on shares of Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) to "Neutral" from "Buy" with $15 price target, saying she still sees long-term value but limited near-term catalysts. [More...]

Related Stocks:

Momenta Phamaceuticals, Inc.

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates